UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-10-31 | Future report Set alerts | |
| Q2 2022 | 2022-08-08 | -0.67 | -0.67 |
| Q1 2022 | 2022-05-03 | -1.08 | -1.08 |
| Q4 2021 | 2022-02-24 | -0.95 | -0.95 |
| Q3 2021 | 2021-11-02 | -0.86 | -0.86 |
| Q2 2021 | 2021-07-29 | -0.66 | -0.66 |
| Q1 2021 | 2021-04-29 | -0.90 | -0.90 |
| Q4 2020 | 2021-02-25 | -0.04 | -0.04 |
| Q3 2020 | 2020-11-04 | 0.00 | 0.00 |
| Q2 2020 | 2020-07-30 | -0.94 | -0.94 |
| 2016-06-30 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-06-14 | Reiterated Rating | Oppenheimer | Buy | |
| 2016-06-14 | Reiterated Rating | Oppenheimer Holdings Inc. | Buy | |
| 2016-05-22 | Reiterated Rating | BTIG Research | Buy | $35.00 |
| 2016-05-19 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-05-19 | Reiterated Rating | Leerink Swann | Outperform | $47.00 |
| 2016-05-18 | Reiterated Rating | Wedbush | Outperform | $52.00 |
| 2016-05-04 | Reiterated Rating | Wedbush | Outperform | $52.00 |
| 2016-04-08 | Boost Price Target | Morgan Stanley | $20.00 to $21.00 | |
| 2016-04-07 | Initiated Coverage | BTIG Research | Buy | $35.00 |
| 2016-02-25 | Initiated Coverage | Morgan Stanley | Equal Weight | $20.00 |
| 2016-02-19 | Lower Price Target | Citigroup Inc. | $37.00 to $27.00 | |
| 2016-02-18 | Initiated Coverage | Janney Montgomery Scott | Buy | $36.00 |
| 2015-10-19 | Upgrade | Citigroup Inc. | Neutral to Buy | $37.00 |
| 2015-10-05 | Reiterated Rating | Roth Capital | Buy | |
| 2015-10-05 | Reiterated Rating | Oppenheimer | Outperform | $48.00 |
| 2015-09-18 | Reiterated Rating | Oppenheimer | Buy | $48.00 |
| 2015-09-17 | Initiated Coverage | Citigroup Inc. | Neutral | $31.00 |
| 2015-08-12 | Reiterated Rating | Oppenheimer | Outperform | $48.00 |
| 2015-08-06 | Reiterated Rating | Stifel Nicolaus | Buy | $51.00 to $56.00 |
| 2015-07-08 | Reiterated Rating | Roth Capital | Buy | |
| 2015-03-09 | Reiterated Rating | Oppenheimer | Outperform | $48.00 |
| 2014-12-15 | Boost Price Target | Roth Capital | Buy | $32.00 to $45.00 |
| 2014-11-12 | Reiterated Rating | Stifel Nicolaus | Buy | $53.00 to $51.00 |
| 2014-07-10 | Initiated Coverage | Oppenheimer | Outperform | $48.00 |
| 2014-06-19 | Boost Price Target | Roth Capital | $28.00 to $30.00 | |
| 2014-06-09 | Initiated Coverage | Roth Capital | Buy | $28.00 |
| 2014-03-21 | Boost Price Target | Stifel Nicolaus | $51.00 to $53.00 | |
| 2014-03-05 | Boost Price Target | Stifel Nicolaus | Buy | $35.00 to $51.00 |
| 2014-02-25 | Boost Price Target | Leerink Swann | Outperform | $34.00 to $52.00 |
| 2014-02-18 | Upgrade | Bank of America | Neutral to Buy | $30.00 to $50.00 |
| 2013-12-03 | Initiated Coverage | Wedbush | Outperform | $70.00 |
| 2013-11-04 | Initiated | Stifel | Buy | $35 |
| 2013-11-04 | Initiated Coverage | Lazard Capital Markets | Buy | |
| 2013-11-04 | Initiated Coverage | Stifel Nicolaus | Buy | $35.00 |
| 2013-11-04 | Initiated Coverage | Leerink Swann | Outperform | $34.00 |
| 2013-11-04 | Initiated Coverage | Bank of America | Neutral | $30.00 |
| 2016-06-30 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-06-14 | Reiterated Rating | Oppenheimer | Buy | |
| 2016-06-14 | Reiterated Rating | Oppenheimer Holdings Inc. | Buy | |
| 2016-05-22 | Reiterated Rating | BTIG Research | Buy | $35.00 |
| 2016-05-19 | Reiterated Rating | Morgan Stanley | Hold |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In MGNX 109 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| ARMISTICE CAPITAL, LLC | 6.13M |
| BlackRock Inc. | 5.72M |
| OPPENHEIMER FUNDS INC | 4.46M |
| Vanguard Group, Inc | 4.18M |
| WASATCH ADVISORS INC | 2.90M |
| BlackRock Fund Advisors | 1.51M |
| FEDERATED INVESTORS INC /PA/ | 1.41M |
| STATE STREET CORP | 1.38M |
| Rock Springs Capital Management LP | 1.21M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.05M |
| ACADIAN ASSET MANAGEMENT LLC | 1.02M |
| TWO SIGMA ADVISERS, LLC | 0.95M |
| EcoR1 Capital, LLC | 0.93M |
| BAKER BROS. ADVISORS LP | 0.89M |
| BlackRock Institutional Trust Company, N.A. | 0.81M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| TPG Group Holdings (SBS) Advisors, Inc. Former 10% Owner | 7.96% (2208762) | AERI / ALDR / CDNA / CZR / EPRS / FSL / GPK / IMS / LPLA / MGNX / NCLH / NTI / OTIC / PKY / Q / ROKA / SABR / SCAI / SUP / TIPT / TMHC / TNDM / VCYT / ZMH / |
| ALTA BIOPHARMA PARTNERS III LP | 7.26% (2013509) | AEGR / CARA / CMRX / MGNX / SNSS / |
| INTERWEST PARTNERS VIII LP | 6.88% (1908716) | AGTC / MGNX / |
| ORONSKY ARNOLD L | 6.16% (1708716) | AGTC / DVAX / MGNX / TSRO / |
| Galbraith Kenneth | 4.75% (1317049) | CPXX / MGNX / |
| Koenig Scott President and CEO | 0.48% (133163) | AGTC / GLYC / MGNX / |
| Bonvini Ezio Senior V P, Research | 0.43% (120026) | MGNX / |
| Karrels James V P, CFO and Secretary | 0.41% (114847) | MGNX / |
| Stein Kathryn E Senior VP, Prd Dev & Reg Aff | 0.34% (95555) | MGNX / |
| Costa Paulo F | 0.21% (59435) | MGNX / |
| Wigginton Jon Marc Senior VP, Clinical Dev. | 0.07% (18930) | MGNX / |
| HURWITZ EDWARD | 0.07% (18074) | AGTC / CARA / MGNX / SNSS / |
| SARAN ATUL See remarks | 0.06% (16986) | EBS / MGNX / XNCR / |
| Cilinski Lynn V P, Controller and Treasurer | 0.04% (9912) | MGNX / |
| Risser Eric Blasius V P, Business Development | 0.03% (9100) | MGNX / |
UM